Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q2 2025 value amounting to -$1.7 million.

  • Day One Biopharmaceuticals' Capital Expenditures fell 10305.45% to -$1.7 million in Q2 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year increase of 248179.42%. This contributed to the annual value of $20.0 million for FY2024, which is 882857.14% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Capital Expenditures of -$1.7 million as of Q2 2025, which was down 10305.45% from $2.0 million recorded in Q1 2025.
  • Day One Biopharmaceuticals' Capital Expenditures' 5-year high stood at $55.0 million during Q2 2024, with a 5-year trough of -$54.2 million in Q3 2024.
  • Over the past 4 years, Day One Biopharmaceuticals' median Capital Expenditures value was $20500.0 (recorded in 2022), while the average stood at $1.7 million.
  • The largest annual percentage gain for Day One Biopharmaceuticals' Capital Expenditures in the last 5 years was 24052500.0% (2024), contrasted with its biggest fall of 13241707.32% (2024).
  • Over the past 4 years, Day One Biopharmaceuticals' Capital Expenditures (Quarter) stood at $4000.0 in 2022, then surged by 100.0% to $8000.0 in 2023, then surged by 240525.0% to $19.2 million in 2024, then plummeted by 108.73% to -$1.7 million in 2025.
  • Its last three reported values are -$1.7 million in Q2 2025, $2.0 million for Q1 2025, and $19.2 million during Q4 2024.